Perth's latest animal health offering names chairman
09 March, 2004 by Renate KrellePerth-based Stirling Products (ASX:STI) -- which debuted on the stock exchange last month via a backdoor listing -- has appointed London-based pharmacologist Prof Clive Page as non-executive chairman.
Proteome Systems, Shimadzu team up in US push
09 March, 2004 by Renate KrelleJapanese instruments specialist Shimadzu Scientific and the US arm of Australia's Proteome Systems will tighten their US collaboration, announcing today that they have agreed to team up on the application support of their jointly-developed proteomics products, Xcise and Chip.
Benitec, Promega launch new RNAi products
05 March, 2004 by Graeme O'NeillBrisbane-based gene technology company Benitec (ASX:BLT) today launched the first commercial gene-silencing vectors to emerge from its global licensing agreement signed with the US-based Promega Corporation in Madison, Wisconsin, in April last year.
R&D grant to speed pathology technology on its way
05 March, 2004 by Renate KrelleEveryone's favourite nightmare -- that they will be falsely diagnosed with a terrible disease because of a mix-up in blood or tissue samples -- is the target of Brisbane-based Ai Scientific's pathology specimen processing technology, which last week received a $3.33 million R&D Start grant from the federal government.
Psivida subsidiary signs US development deal
04 March, 2004 by Melissa TrudingerPsiMedica, the UK-based subsidiary of Australian nanotechnology company Psivida (ASX:PSD), has signed a materials transfer agreement with US nanotech company NanoHorizons.
Avastin approval is great news for biotech, say pundits
04 March, 2004 by Melissa TrudingerLast week's thumbs-up by the US Food and Drug Administration for Genentech's anti-angiogenesis drug Avastin (bevacizumab) for the treatment of metastatic colorectal cancer has widespread implications both for cancer therapy and biotechnology in general, according to industry observers.
Virax booms on cancer vaccine trial news
03 March, 2004 by Melissa TrudingerVirax's share price has soared after the company disclosed that French biotech company Transgene recently reported promising interim results from Phase II trials of a cancer therapeutic vaccine based on the Virax's Co-X-Gene technology.
Ventracor implant not implicated in patient death
03 March, 2004 by Melissa TrudingerArtificial heart developer Ventracor (ASX:VCR) has reported that the fifth patient to be implanted with the company's VentrAssist device has died at the Alfred Hospital, about a month after receiving the implant.
Progen skyrockets on Genentech news
02 March, 2004 by Melissa TrudingerBrisbane-based Progen is riding high on the US Food and Drug Administration's approval of Genentech's anti-angiogenesis drug Avastin.
AGT and Garvan team up to target diabetes
02 March, 2004 by Renate KrelleAGT Biosciences (ASX: AGT) has expanded its stable of programs in diabetes and obesity research, signing a collaborative research agreement with Sydney's Garvan Institute of Medical Research to identify molecules as potential therapeutics for type II diabetes.
Australia's capital territory set to ban GM crops
02 March, 2004 by Graeme O'NeillThe Australian Capital Territory, home to CSIRO's Plant Industry division, looks set to join the southern mainland states and Tasmania in imposing a moratorium on the environmental release of genetically modified crops.
Qld's Tissue Therapies aims for $3.5m IPO
01 March, 2004 by Melissa TrudingerQueensland University of Technology spin-off Tissue Therapies is seeking to raise AUD$3.5 million in an initial public offering of seven million shares at $0.50.
Amrad nets second Merck milestone payment
01 March, 2004 by Melissa TrudingerAmrad has received a second US$3 million milestone payment from Merck, Sharp and Dohme, bringing the total payments to the company under the terms of the agreement to $11 million to date out of a possible $112 million.
Peptech draws strength from antibodies, new and old
27 February, 2004 by Renate KrellePeptech's (ASX:PTD) recent investment in UK domain antibody specialist Domantis took centre stage at the company's annual general meeting today, despite shareholder discontent regarding an employee performance share plan.
Macfarlane pledges continued biotech support
27 February, 2004 by Melissa TrudingerThe biotechnology industry is likely to be one of the beneficiaries of the forthcoming successor to the Backing Australia's Ability program, according to federal industry minister Ian Macfarlane.
